Acta Scientific Microbiology (ISSN: 2581-3226)

Research Article Volume 5 Issue 5

Effects of Platinum-based Chemotherapeutic Agents on ML-1 Thyroid Cancer Cells

Daniel S Kim1, Min Zhang2, Nhi Le2, Seth Harris2 and Kyoungtae Kim2*

1Emory College of Arts and Science, USA
2Department of Biology, Missouri State University, USA

*Corresponding Author: Kyoungtae Kim, Department of Biology, Missouri State University, USA.

Received: April 04, 2022; Published: April 29, 2022

Abstract

Recent literature demonstrates that platinum-based chemotherapeutic drugs in physiological solvents display higher efficacy in destabilizing cancer cells. As human cancer cells come in over 200 different varieties, it would be beneficial to test the efficacy of these drugs using a wider spectrum of cells. Utilizing the well-tested HeLa cervical cancer cells as a control for the effects of these drugs, we assessed the impact of platinum-based cisplatin, carboplatin, and oxaliplatin on ML-1 thyroid cancer cells. Through the XTT Viability assay, we found that ML-1 cells are more resistant to cisplatin and oxaliplatin with an IC50 value at least four times higher than those for the same drugs in HeLa cells. It has been consistently shown that the oxidative stress caused by these chemicals was more pronounced in HeLa cells than in ML-1 cells, but the only measurable results were found 24 hours after treatment. We also show that a high percentage of HeLa cells displayed apoptosis with even 20 mM of these chemicals, which is directly comparable in effect to the 100 mM of chemicals in ML-1 cells. Upon comparing the expression levels of pro-apoptotic enzymes in HeLa and ML-1 cells, we observed that when treated with 40 mM of these chemicals, the levels of pro-apoptotic enzymes were statistically higher for HeLa cells than for ML-1 cells. Our research will provide new insight into the different capacities of each cell line and the treatment regimen for cancer patients in the future.

Keywords: ML-1; HeLa; Cisplatin; Cytotoxicity; Resistance

References

  1. Cancer-Facts-and-Figures-2021.Pdf, American Cancer Society (2021).
  2. S Schoch., et al. “Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics”. International Journal of Molecular Sciences18 (2020).
  3. JP Becker., et al. “Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation”. Toxicology Letter1 (2014) 43-47.
  4. S Dasari and PB Tchounwou. “Cisplatin in cancer therapy: molecular mechanisms of action”. European Journal of Pharmacology 740 (2014): 364-378.
  5. RK Mehmood. “Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments”. Oncology Review2 (2014): 256.
  6. GF De Sousa., et al. “Carboplatin: molecular mechanisms of action associated with chemoresistance”. Brazilian Journal of Pharmaceutical 4 (2014).
  7. DA Pereira and JA Williams. “Origin and evolution of high throughput screening”. British Journal of Pharmacology 1 (2007): 53-61.
  8. SJ Kerrison and PJ Sadler. “Solvolysis of Cis-Pt (NH3)2Cl2. in Dimethyl Sulphoxide and Reactions of Glycine with PtCl3 (Me 2SO).- as Probed by 195Pt Nuclear Magnetic Resonance Shifts and 195Pt-15N Coupling Constants”. Journal of the Chemical Society, Chemical Communications 23 (1977).
  9. N Farrell., et al. “Chemical Properties and Antitumor Activity of Complexes of Platinum Containing Substituted Sulfoxides PtCl (R′R″SO) (Diamine).NO3. Chirality and Leaving-Group Ability of Sulfoxide Affecting Biological Activity”. Inorganic Chemistry3 (1990).
  10. YW Yi and I Bae. “Effects of solvents on in vitro potencies of platinum compounds”. DNA Repair (Amst)11 (2011): 1084-1085.
  11. HP Varbanov., et al. “Oxaliplatin reacts with DMSO only in the presence of water”. Dalton Transactions28 (2017): 8929-8932.
  12. MD Hall., et al. “Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes”. Cancer Research14 (2014): 3913-3922.
  13. H Rizvanovic., et al. “Chlorotoxin Conjugated with Saporin Reduces Viability of ML-1 Thyroid Cancer Cells in Vitro”. BioRxiv (2019).
  14. H Rizvanovic and K Kim. “Novel Cyanoximate Pt (DECO)2 as an Anti-Cancer Drug Using ML1 Thyroid Cancer Cells”. Acta Scientific Microbiology6 (2021).
  15. D Ali., et al. “ROS- dependent Bax/Bcl2 and caspase 3 pathway-mediated apoptosis induced by zineb in human keratinocyte cells”. OncoTargets and Therapy 11 (2018): 489-497.
  16. G Valdameri., et al. “Involvement of catalase in the apoptotic mechanism induced by apigenin in HepG2 human hepatoma cells”. Chemico-Biological Interactions 2 (2011): 180-189.
  17. A Haque., et al. “MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer”. Frontiers in Genetics 11 (2020): 516.
  18. J Davis., et al. “DMSO reduces the cytotoxicity of anticancer ruthenium complex KP1019 in yeast”. MicroPublication Biology 2021 (2021).
  19. SW Tanley., et al. “Structural studies of the effect that dimethyl sulfoxide (DMSO) has on cisplatin and carboplatin binding to histidine in a protein”. Acta Crystallographica Section D 68 (Pt 5) (2012): 601-612.
  20. MR Spitz., et al. “Integrative epidemiology: from risk assessment to outcome prediction”. Journal of Clinical Oncology2 (2005): 267-275.
  21. RS Huang., et al. “Effect of population and gender on chemotherapeutic agent-induced cytotoxicity”. Molecular Cancer Therapeutics1 (2007): 31-36.
  22. L Florento., et al. “Comparison of Cytotoxic Activity of Anticancer Drugs against Various Human Tumor Cell Lines Using In Vitro Cell-Based Approach”. International Journal of Biomedical Science 1 (2012): 76-80.

Citation

Citation: Kyoungtae Kim., et al. “Effects of Platinum-based Chemotherapeutic Agents on ML-1 Thyroid Cancer Cells". Acta Scientific Microbiology 5.5 (2022): 128-139.

Copyright

Copyright: © 2022 Kyoungtae Kim.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days

Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US